Sam Whiting M.D.

Sam Whiting MD PhD is a highly experienced medical professional with extensive expertise in oncology and clinical development. Currently serving as Chief Medical Officer at Vividion Therapeutics, Inc. since August 2025, Whiting previously held senior roles at Tempest Therapeutics, where responsibilities included Chief Medical Officer and Head of Research and Development, and at Calithera Biosciences as Senior Vice President of Clinical Development. Whiting's notable roles also include leadership positions at Gradalis Inc., Mary Crowley Cancer Research Centers, VentiRx, and Oncothyreon, along with academic appointments at the University of Washington and Fred Hutchinson Cancer Research Center. Educational qualifications include an MD PhD obtained through the NIH Medical Scientist Training Program at the University of Washington, and a Bachelor’s Degree in Chemistry from Lewis & Clark College.